Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hongwu International Group is a prominent manufacturer and supplier of nanomaterials, specializing in the research, development, and production of nanoparticles and nanopowders. Founded in 2002, the company operates primarily through its subsidiary, Guangzhou Hongwu Material Technology, and serves a global market across various high-tech industries. In the life sciences and healthcare sectors, Hongwu provides essential materials such as silver nanoparticles for antibacterial applications and gold nanoparticles for diagnostic biosensors. Their product portfolio also includes carbon nanotubes and various metal oxides used in targeted drug delivery research and bio-imaging. The company maintains advanced manufacturing facilities capable of high-purity synthesis and customized dispersion services. By bridging materials science and biotechnology, Hongwu supports the development of next-generation medical devices and therapeutic platforms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hongwu International Group.